Cintia Piccina - 03 Jul 2023 Form 4 Insider Report for Allovir, Inc. (KLRS)

Role: Chief Commercial Officer
Signature: /s/ Brett Hagen, as Attorney-in-Fact
Issuer symbol: KLRS
Transactions as of: 03 Jul 2023
Net transactions value: $0
Form type: 4
Filing time: 05 Jul 2023, 17:00:20 UTC
Previous filing: 21 Jun 2023
Next filing: 18 Mar 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALVR	Common Stock	Award	$0	+147,000		$0.000000	147,000	03 Jul 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALVR	Stock Option (Right to Buy)	Award	$0	+273,000		$0.000000	273,000	03 Jul 2023	Common Stock	273,000	$3.24	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on June 12, 2024, with the remainder vesting in twelve equal quarterly installments thereafter.
F2	25% of this option shall vest and become exercisable on June 12, 2024, with the remainder vesting in twelve equal quarterly installments thereafter.